ClinicalTrials.gg
Active, not recruitingNCT06055816Updated Oct 6, 2026

Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

A Phase 2 interventional study of Endostar and Envafolimab in Nasopharyngeal Carcinoma, sponsored by Zhejiang Cancer Hospital. Active, not recruiting at 1 site in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Zhejiang Cancer Hospital · Phase 2, Interventional, and Treatment

How we know

Updated Oct 6, 2026Now Active, not recruitingStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Nasopharyngeal Carcinoma by Zhejiang Cancer Hospital — 6 open to participants now, 8 under way, none of them phase 3. Nasopharyngeal Carcinoma · Zhejiang Cancer Hospital.

Planned enrollment
15th of 19
40 · median 60
Started
2023
with 1 other
Phase 2
13 of 23
4 open now
Registered
21st of 23
by date

Among the 23 studies in Nasopharyngeal Carcinoma by Zhejiang Cancer Hospital, this one is the 15th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2023, is one of 13 in phase 2, and was the 21st registered.

Nasopharyngeal Carcinoma

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

Browse Nasopharyngeal Carcinoma studies →

Open to participants now

6 of the 23 studies in Nasopharyngeal Carcinoma by Zhejiang Cancer Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Nasopharyngeal Carcinoma by Zhejiang Cancer Hospital, or all of them as a file.
02

Study summary

Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

03

Conditions studied

  • Nasopharyngeal Carcinoma
04

Who can participate

The criteria were revised on the registry on Oct 6, 2026. See what changed

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥65 years with newly confirmed NPC
  • score: 0 to 1.
  • Clinical stage III-IVA (Union for International Cancer Control and American Joint Committee on Cancer staging system for NPC, 8th edition)
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • positive with a hepatitis B virus quantification > 1×10³ copies/mL or anti- positive.
  • Anti- positive or AIDS diagnosis
  • Active tuberculosis: within the past year.
  • Active or suspected diseases (e.g., uveitis, enteritis, hepatitis), excluding stable type I diabetes, treated hypothyroidism, or mild skin conditions
  • Interstitial lung disease or pneumonia requiring oral or intravenous therapy within the past year.
  • Chronic systemic glucocorticoids or therapy (≥10 mg prednisone/day); inhaled/topical corticosteroids permitted.
  • Uncontrolled cardiovascular disease (e.g., [NYHA] ≥ II heart failure, recent myocardial infarction, unstable angina, significant arrhythmias).
  • History of other (except adequately treated non-melanoma skin cancer, in situ cervical carcinoma, or papillary thyroid cancer).
  • Known allergy to envafolimab or its components.
  • Active infection within a week requiring systemic therapy.
  • Receiving a within 30 days prior to first envafolimab dose
  • History of organ transplantation.
  • Any condition deemed by investigators to interfere with safety or protocol adherence (e.g., serious comorbidity, severe lab abnormalities, or psychosocial issues).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Gemcitabine Combined With Endostar and Envafolimab

    Neoadjuvant therapy consisting of gemcitabine (1000mg/m2 d1,8) , endostar (150mg 3-day continuous infusion) and envafolimab (240mg d1) was given every 3 weeks for 3 cycles. Endostar, administered every 3 weeks (150mg 3-day continuous infusion), was given concurrently with intensity-modulated radiotherapy.

    Drug: Endostar and Envafolimab

Interventions

  • DrugEndostar and Envafolimab

    Drug pages: Endostar proteinStudies of Endostar proteinEndostar protein pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · EnvafolimabStudies of EnvafolimabEnvafolimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Neoadjuvant therapy consisting of gemcitabine (1000mg/m2 d1,8) , endostar (150mg 3-day continuous infusion) and envafolimab (240mg d1) was given every 3 weeks for 3 cycles. Endostar, administered every 3 weeks (150mg 3-day continuous infusion), was given concurrently with intensity-modulated radiotherapy.

06

What researchers measure

Primary outcomes

  1. The proportion of patients with grade 3 or higher adverse events (AEs).

    The primary endpoint was the safety profile. AEs were scored according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    Time frame: Up to 24 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in May 2026, 30 months.

Of 128 non-industry phase 2 interventional studies under Nasopharyngeal Carcinoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 74. This study's 30 months is below that.

Counting every sponsor, half of 143 studies reached it within 43 months; a quarter within 28 and three quarters within 65.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: start Sep 2023 → Oct 2023 and primary completion Sep 2024 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2023
First posted
Sep 28, 2023
StartActual
Oct 24, 2023was Sep 2023
Primary completionActual
May 9, 2026was Sep 2024
CompletionEst.
Jun 30, 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 6, 2026
Start date
Sep 28, 2023→Oct 24, 2023 (actual)
Oct 6, 2026
Primary completion
Sep 30, 2024→May 9, 2026 (actual)
Oct 6, 2026
Eligibility
Criteria largely rewritten (18 changes)
What changed in the criteria
Inclusion criteria
  • RemovedKarnofsky performance status ≥60
  • AddedECOG score: 0 to 1.
Exclusion criteria
  • RemovedCancer history
  • RemovedPrior radiotherapy, cytotoxic chemotherapy, immunotherapy or target therapy
  • RemovedLife-expectance within 6 months
  • AddedHBsAg positive with a hepatitis B virus quantification > 1×10³ copies/mL or anti-HCV positive.
  • AddedAnti-HIV positive or AIDS diagnosis
  • AddedActive tuberculosis: within the past year.
  • AddedActive or suspected autoimmune diseases (e.g., uveitis, enteritis, hepatitis), excluding stable type I diabetes, treated hypothyroidism, or mild skin conditions
  • AddedInterstitial lung disease or pneumonia requiring oral or intravenous steroid therapy within the past year.
  • AddedChronic systemic glucocorticoids or immunosuppressive therapy (≥10 mg prednisone/day); inhaled/topical corticosteroids permitted.
  • AddedUncontrolled cardiovascular disease (e.g., New York Heart Association [NYHA] ≥ II heart failure, recent myocardial infarction, unstable angina, significant arrhythmias).
  • AddedHistory of other malignancies (except adequately treated non-melanoma skin cancer, in situ cervical carcinoma, or papillary thyroid cancer).
  • AddedKnown allergy to envafolimab or its components.
  • AddedActive infection within a week requiring systemic therapy.
  • AddedReceiving a live vaccine within 30 days prior to first envafolimab dose
  • AddedHistory of organ transplantation.
  • AddedAny condition deemed by investigators to interfere with safety or protocol adherence (e.g., serious comorbidity, severe lab abnormalities, or psychosocial issues).
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Recruiting→Active, not recruiting
    Start date Sep 28, 2023→Oct 24, 2023 (now actual)
    Primary completion Sep 30, 2024→May 9, 2026 (now actual)
    Eligibility Criteria largely rewritten (18 changes)
    What changed in the criteria
    Inclusion criteria
    • RemovedKarnofsky performance status ≥60
    • AddedECOG score: 0 to 1.
    Exclusion criteria
    • RemovedCancer history
    • RemovedPrior radiotherapy, cytotoxic chemotherapy, immunotherapy or target therapy
    • RemovedLife-expectance within 6 months
    • AddedHBsAg positive with a hepatitis B virus quantification > 1×10³ copies/mL or anti-HCV positive.
    • AddedAnti-HIV positive or AIDS diagnosis
    • AddedActive tuberculosis: within the past year.
    • AddedActive or suspected autoimmune diseases (e.g., uveitis, enteritis, hepatitis), excluding stable type I diabetes, treated hypothyroidism, or mild skin conditions
    • AddedInterstitial lung disease or pneumonia requiring oral or intravenous steroid therapy within the past year.
    • AddedChronic systemic glucocorticoids or immunosuppressive therapy (≥10 mg prednisone/day); inhaled/topical corticosteroids permitted.
    • AddedUncontrolled cardiovascular disease (e.g., New York Heart Association [NYHA] ≥ II heart failure, recent myocardial infarction, unstable angina, significant arrhythmias).
    • AddedHistory of other malignancies (except adequately treated non-melanoma skin cancer, in situ cervical carcinoma, or papillary thyroid cancer).
    • AddedKnown allergy to envafolimab or its components.
    • AddedActive infection within a week requiring systemic therapy.
    • AddedReceiving a live vaccine within 30 days prior to first envafolimab dose
    • AddedHistory of organ transplantation.
    • AddedAny condition deemed by investigators to interfere with safety or protocol adherence (e.g., serious comorbidity, severe lab abnormalities, or psychosocial issues).
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06055816
Responsible party
Chen Xiaozhong (Professor, Zhejiang Cancer Hospital) — Principal investigator
First posted
Sep 28, 2023
Start date
Oct 24, 2023
Primary completion
May 9, 2026
Completion
Jun 30, 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

Xiaozhong Chen
principal investigator · Department of Radiation Oncology, Zhejiang Cancer Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Endostar protein · Envafolimab

Start the discussion